Clinical Trial Details
| Trial ID: | L6964 |
| Source ID: | NCT02016911 |
| Associated Drug: | Semaglutide |
| Title: | Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes|Diabetes Mellitus, Type 2|Healthy |
| Interventions: | DRUG: semaglutide |
| Outcome Measures: | Primary: Area under the semaglutide plasma concentration curve, From time 0 to 24 hours after the 10th dosing | Secondary: Maximum observed semaglutide plasma concentration, 0 to 24 hours after the 10th dosing|Area under the SNAC (Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate /salcaprozate sodium) plasma concentration time curve, From time 0 to 24 hours after the 10th dosing|Maximum observed SNAC plasma concentration, 0 to 24 hours after the 10th dosing |
| Sponsor/Collaborators: | Sponsor: Novo Nordisk A/S |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE1 |
| Enrollment: | 56 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2013-12-12 |
| Completion Date: | 2015-01-12 |
| Results First Posted: | |
| Last Update Posted: | 2018-05-15 |
| Locations: | Novo Nordisk Investigational Site, Praha 10, 10034, Czechia|Novo Nordisk Investigational Site, Praha 7, 17000, Czechia|Novo Nordisk Investigational Site, Bialystok, 15-879, Poland|Novo Nordisk Investigational Site, Warszawa, 02-507, Poland|Novo Nordisk Investigational Site, Wolomin, 05-200, Poland|Novo Nordisk Investigational Site, Bratislava, 83101, Slovakia |
| URL: | https://clinicaltrials.gov/show/NCT02016911 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|